CI
TVTX icon

Cordant Inc’s Travere Therapeutics TVTX Stock Holding History

Cordant Inc’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$152 Buy
+3
New +$133 ﹤0.01% 305

Other funds holding TVTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
BC
Burney Company Reston, Virginia $3.71B AUM 37.66% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DT
Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
SWM
Spire Wealth Management Mclean, Virginia $3.31B AUM 38.78% 1-Year Est. Return
EB
Eastern Bank Boston, Massachusetts $6.53B AUM 30.05% 1-Year Est. Return

Cordant Inc's TVTX Position: Q2 2026 in Review

Cordant Inc opened a new position in Travere Therapeutics (TVTX) in Q2 2026: 3 shares worth $152. The stake represents ﹤0.01% of the portfolio and ranks #305 among its holdings.

17 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Cordant Inc held 3 shares of Travere Therapeutics worth $152 as of Q2 2026.
  • Travere Therapeutics was a new Cordant Inc position in Q2 2026.
  • Travere Therapeutics made up ﹤0.01% of Cordant Inc's portfolio in Q2 2026, its #305 holding.
  • 17 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Cordant Inc's 13F filing for Q2 2026, filed 15 Jul 2026.